Collaborative HIV Seroincidence Study

Collaborative HIV Seroincidence Study
Name	Collaborative HIV Seroincidence Study
Acronym	CHSS
Study type	Cohort study
Start date	1990s
Location	United States
Investigators	Multiple institutions
Funding	Federal grants

Collaborative HIV Seroincidence Study

The Collaborative HIV Seroincidence Study was a multicenter cohort investigation conducted in the United States to measure HIV seroincidence and evaluate risk factors among diverse populations. It involved partnerships among academic centers, public health agencies, and community organizations to track seroconversion, inform prevention policy, and guide clinical practice. The study produced influential data used by policymakers, clinicians, and researchers across epidemiology and infectious disease fields.

Background

The study emerged amid rising attention to the HIV epidemic in the late 20th century, when institutions such as the Centers for Disease Control and Prevention and the National Institutes of Health increased funding for cohort research. Investigators affiliated with universities including Johns Hopkins University, Columbia University, University of California, San Francisco, Harvard University, and Yale University collaborated with municipal health departments like the New York City Department of Health and Mental Hygiene and the San Francisco Department of Public Health. The project drew on precedents including the Multicenter AIDS Cohort Study, the Women's Interagency HIV Study, and international efforts like the Rakai Project to design standardized protocols and laboratory assays.

Methods

The study deployed longitudinal serologic testing, behavioral surveys, and clinical follow-up at sites across metropolitan areas including New York City, San Francisco, Los Angeles, Chicago, and Washington, D.C.. Laboratory methods incorporated enzyme-linked immunosorbent assay platforms used by laboratories affiliated with Quest Diagnostics, Laboratory Corporation of America, and academic clinical laboratories such as those at Massachusetts General Hospital and UCLA Medical Center. Cohort recruitment strategies engaged community-based organizations like Gay Men's Health Crisis, San Francisco AIDS Foundation, and AIDS Healthcare Foundation and leveraged referrals from clinics such as Fenway Health and Callen-Lorde Community Health Center. Data management employed systems developed with input from Centers for Disease Control and Prevention informatics teams and biostatistical analysis from departments at University of Michigan, University of California, Berkeley, and Columbia University Mailman School of Public Health.

Results

Findings quantified incidence rates stratified by risk groups identified through linkage to clinics like Montefiore Medical Center and surveillance overseen by agencies including the New York State Department of Health and the California Department of Public Health. Results highlighted elevated seroincidence among cohorts associated with venues such as Stonewall Inn-adjacent networks and neighborhoods in Harlem, Castro District and underscored prevention gaps noted in populations served by the Ryan White HIV/AIDS Program clinics. The study data paralleled outcomes reported in trials run by organizations like the American Foundation for AIDS Research and informed modeling used by groups such as the Institute for Health Metrics and Evaluation and the Kaiser Family Foundation.

Public Health Impact

Policy changes at federal agencies including the Department of Health and Human Services and state health departments drew on the study's incidence estimates to revise testing recommendations from bodies like the United States Preventive Services Task Force and the Advisory Committee on Immunization Practices. The evidence influenced programs funded through the Ryan White HIV/AIDS Program and global initiatives coordinated with stakeholders such as the World Health Organization and the Joint United Nations Programme on HIV/AIDS. Clinical guidelines promulgated by professional societies including the Infectious Diseases Society of America and the American Public Health Association referenced seroincidence data when advising screening intervals and prevention counseling.

Limitations

The study faced challenges common to multicenter cohorts, including selection bias from clinic-based recruitment involving sites such as Mount Sinai Hospital and Brigham and Women's Hospital and loss to follow-up analogous to attrition documented in cohorts like the Multicenter AIDS Cohort Study. Laboratory assay evolution — with newer tests developed by manufacturers like Abbott Laboratories and Bio-Rad Laboratories — complicated temporal comparisons. Generalizability was constrained in rural settings beyond metropolitan networks in Atlanta, Houston, and Miami where enrollment was limited, echoing gaps noted in surveillance reports from the Florida Department of Health and the Georgia Department of Public Health.

Ethical and Regulatory Considerations

Ethical oversight involved institutional review boards at institutions including Columbia University Irving Medical Center, University of California, San Francisco School of Medicine, and Johns Hopkins Bloomberg School of Public Health and compliance with regulations administered by the Department of Health and Human Services. Consent processes were informed by community advisory boards comprising representatives from ACT UP, Lambda Legal, and local advocacy groups, and the study navigated privacy protections under statutes such as the Health Insurance Portability and Accountability Act of 1996. Data sharing arrangements balanced access for investigators at centers like Fred Hutchinson Cancer Research Center and Emory University with confidentiality expectations upheld by municipal authorities including the Chicago Department of Public Health.

Legacy and Subsequent Research

The study's datasets enabled secondary analyses by researchers at institutions including Princeton University, Stanford University, Brown University, Duke University, and University of North Carolina at Chapel Hill and catalyzed trials in prevention science connected to networks like the HIV Prevention Trials Network and the Microbicide Trials Network. Insights influenced biomedical advances pursued by pharmaceutical companies such as Gilead Sciences and Merck & Co. and supported modeling work featured in reports from the Pew Charitable Trusts and the Brookings Institution. Subsequent cohort studies and surveillance projects drew methodological lessons from the study to improve incidence estimation in initiatives led by the European Centre for Disease Prevention and Control and national programs in countries including South Africa, Brazil, and Thailand.

Category:Epidemiology studies